Seema Singhal, MD
Hematology · Chicago, ILNPI 1013940501
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,095 of the $65,078 with a category attached, or 87.7%. 7 manufacturers reported payments, led by Johnson & Johnson at 38.1% of the total. Reporting peaked in 2019 at $55,017 and has fallen 99.3% since, to $362 in 2022.
Across 47 payments — averaging $1384.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$25K
- Takeda Pharmaceuticals U.S.A., Inc.$21K
- Bristol Myers Squibb$12K
- GSK$6K
- Janssen Research & Development, LLC$1K
- Menarini Silicon Biosystems, Inc.$362
- plus $93 from 1 others
Across 112 payments — averaging $22,090 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$1.1M
- Janssen Research & Development, LLC$723K
- Menarini Silicon Biosystems, Inc.$317K
- GSK$156K
- Pfizer$109K
- Takeda Pharmaceuticals U.S.A., Inc.$70K
- plus $20K from 2 others
What the payments were for
- Consulting fees$9001%
- Speaking & faculty fees$57,09588%
- Travel & lodging$5,5669%
- Food & beverage$1,5172%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 17 | $24,794 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $20,539 |
| Bristol Myers Squibb | 8 | $12,162 |
| GSK | 2 | $6,000 |
| Janssen Research & Development, LLC | 6 | $1,128 |
| Menarini Silicon Biosystems, Inc. | 1 | $362 |
| EMD Serono, Inc. | 1 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DARZALEX$24,648
- NINLARO$20,299
- Revlimid$12,162
- BLENREP$6,000
- CELLSEARCH$362
How this compares
$65,078 in reported general payments places this provider in the 80th percentile of 49 hematology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 173 | $2,792,887 |
| PomalystPomalidomide | 138 | $2,579,425 |
| BrukinsaZanubrutinib | 59 | $874,304 |
| Lenalidomide | 43 | $543,947 |
| ImbruvicaIbrutinib | 25 | $375,712 |
| NinlaroIxazomib Citrate | 11 | $101,880 |
| ThalomidThalidomide | 16 | $94,877 |
| EliquisApixaban | 14 | $6,626 |
| Dexamethasone | 65 | $2,339 |
| Acyclovir | 197 | $2,108 |
| ValacyclovirValacyclovir Hcl | 12 | $670 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 72 | $503 |
| Potassium Chloride | 15 | $205 |
| Ondansetron OdtOndansetron | 24 | $150 |
| Ondansetron Hcl | 16 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Thalomid | $12,162 | $2,887,764189 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $20,539 | $101,88011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 hematology providers in Illinois.
Other hematology in Chicago
- Jayesh MehtaChicago$183K
- Celalettin UstunChicago$153K
- Kunal DesaiChicago$150K
- John QuigleyChicago$132K
- Parameswa VenugopalChicago$122K
- Nadia KhanChicago$66K
- Olga FrankfurtChicago$49K
- Deborah KatzChicago$38K
- Martin TallmanChicago$28K
- Robert SteinChicago$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.